Choosing the best second-line tyrosine kinase inhibitor in imatinib-resistant chronic myeloid leukemia patients harboring bcr-abl kinase domain mutations: How reliable is the IC50?

Oncologist

Volumn 16, Issue 6, 2011, Pages 868-876

  Soverini, Simona ^a   Rosti, Gianantonio ^a   Iacobucci, Ilaria ^a   Baccarani, Michele ^a   Martinelli, Giovanni ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; DASATINIB; DEXAMETHASONE; IMATINIB; MUTANT PROTEIN; NILOTINIB; PHENOBARBITAL; PHOSPHOTRANSFERASE; PROGESTERONE; RIFAMPICIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER PATIENT; CELL PROLIFERATION; CHEMOSENSITIVITY; CHRONIC MYELOID LEUKEMIA; CONCENTRATION RESPONSE; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INDICATION; DRUG POTENCY; ENZYME PHOSPHORYLATION; FOOD DRUG INTERACTION; HUMAN; IC 50; IN VIVO STUDY; LEUKEMIA CELL; ONCOGENE; ONCOGENE BCR ABL; POINT MUTATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; RELIABILITY; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; HUMANS; INHIBITORY CONCENTRATION 50; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PHOSPHORYLATION; PIPERAZINES; POINT MUTATION; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; THIAZOLES;

EID: 79959577596     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2010-0388     Document Type: Article

References (65)

1. Nowell PC, Hungerford DA. Chromosome studies on normal and leukemic human leukocytes. J Natl Cancer Inst 1960;25:85-109.
2. Rowley JD. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973;243:290-293.
3. Groffen J, Stephenson JR, Heisterkamp N et al. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 1984;36:93-99.
4. Lugo TG, Pendergast AM, Muller AJ et al. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 1990;247: 1079-1082.
5. Cohen MH, Williams G, Johnson JR et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res 2002;8:935-942.
6. Deininger M. Resistance and relapse with imatinib in CML: Causes and consequences. J Natl Compr Canc Netw 2008;6(suppl 2):S11-S21.
7. Baccarani M, Cortes J, Pane F et al. Chronic myeloid leukemia: An update of concepts and management recommendationsof European Leukemia Net. J Clin Oncol 2009;27:6041-6051.
8. Baccarani M, Saglio G, Goldman J et al. Evolving concepts in the manage-mentof chronic myeloid leukemia: Recommendations fromanexpert panel on behalf of the European LeukemiaNet. Blood 2006;108:1809-1820.
9. Apperley JF. Part I: Mechanisms of resistance to imatinib in chronic my-eloid leukaemia. Lancet Oncol 2007;8:1018-1029.
10. Gorre ME, Mohammed M, Ellwood K et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293:876-880.
11. Nagar B, Bornmann WG, Pellicena P et al. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res 2002;62:4236-4243.
12. Corbin AS, Buchdunger E, Pascal F et al. Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571. J Biol Chem 2002; 277:32214-32219.
13. Lee TS, Potts SJ, Kantarjian H et al. Molecular basis explanation for ima-tinib resistance of BCR-ABL due to T315I and P-loop mutations from molecular dynamics simulations. Cancer 2008;112:1744-1753.
14. Lee TS, Potts SJ, Albitar M. Basis for resistance to imatinib in 16 BCR-ABL mutants as determined using molecular dynamics. Recent Pat Anti-cancer Drug Discov 2009;4:164-173.
15. Corbin AS, LaRosée P, Stoffregen EP et al. Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood 2003;101:4611-4614.
16. Shah NP, Nicoll JM, Nagar B et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002;2:117-125.
17. Azam M, Latek RR, Daley GQ. Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 2003; 112:831-843.
18. O'Hare T, Walters DK, Stoffregen EP et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005;65:4500-4505.
19. Weisberg E, Manley PW, Breitenstein W et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005;7:129-141.
20. Burgess MR, Skaggs BJ, Shah NP et al. Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance. Proc Natl Acad Sci U S A 2005;102:3395-3400.
21. Manley PW, Cowan-Jacob SW, Mestan J. Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia. Biochim Biophys Acta 2005; 1754:3-13.
22. Bradeen HA, Eide CA, O'Hare T et al. Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitro-sourea (ENU)-based mutagenesis screen: High efficacy of drug combinations. Blood 2006;108:2332-2338.
23. Ray A, Cowan-Jacob SW, Manley PW et al. Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study. Blood 2007;109:5011-5015.
24. Redaelli S, Piazza R, Rostagno R et al. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. J Clin Oncol 2009;27:469-471.
25. Zhou T, Parillon L, Li F et al. Crystal structure of the T315I mutant of Abl kinase. Chem Biol Drug Des 2007;70:171-181.
26. Iacob RE, Pene-Dumitrescu T, Zhang J et al. Conformational disturbance in Abl kinase upon mutation and deregulation. Proc Natl Acad Sci USA 2009;106:1386-1391.
27. O'Hare T, Eide CA, Deininger MW. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 2007;110:2242-2249.
28. Mller MC, Cortes JE, Kim DW et al. Dasatinib treatment of chronic-phase chronic myeloid leukemia: Analysis of responses according to preexisting BCR-ABL mutations. Blood 2009;114:4944-4953.
29. Hochhaus A, Kantarjian HM, Baccarani M et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 2007;109:2303-2309.
30. Hughes T, Saglio G, Branford S et al. Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. J Clin Oncol 2009;27:4204-4210.
31. Jabbour E, Jones D, Kantarjian HM et al. Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations. Blood 2009;114:2037-2043.
32. Cortes J, Jabbour E, Kantarjian H et al. Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. Blood 2007;110:4005-4011.
33. Soverini S, Martinelli G, Colarossi S et al. Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia. J Clin Oncol 2006;24:e51-e52.
34. Soverini S, Colarossi S, Gnani A et al. Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain. Haematologica 2007;92:402-404.
35. Soverini S, Gnani A, Colarossi S et al. Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. Blood 2009;114: 2168-2171.
36. Khorashad JS, Milojkovic D, Mehta P et al. In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib. Blood 2008;111:2378-2381.
37. Shah NP, Skaggs BJ, Branford S et al. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J Clin Invest 2007;117:2562-2569.
38. Soverini S, Martinelli G, Colarossi S et al. Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALL. Lancet Oncol 2007;8:273-274.
39. Hochhaus A, Kreil S, Corbin AS et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002;16: 2190-2196.
40. Campbell LJ, Patsouris C, Rayeroux KC et al. BCR/ABL amplification in chronic myelocytic leukemia blast crisis following imatinib mesylate administration. Cancer Genet Cytogenet 2002;139:30-33.
41. Morel F, Bris MJ, Herry A et al. Double minutes containing amplified bcr-abl fusion gene in a case of chronic myeloid leukemia treated by imatinib. Eur J Haematol 2003;70:235-239.
42. Cortes JE, Talpaz M, Giles F et al. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Blood 2003;101:3794-3800.
43. Schoch C, Haferlach T, Kern W et al. Occurrence of additional chromosome aberrations in chronic myeloid leukemia patients treated with ima-tinib mesylate. Leukemia 2003;17:461-463.
44. Lahaye T, Riehm B, Berger U et al. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: A 4.5-year follow-up. Cancer 2005;103:1659-1669.
45. Jabbour E, Kantarjian H, Jones D et al. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia 2006;20:1767-1773.
46. White DL, Saunders VA, Dang P et al. OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): Reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood 2006;108:697-704.
47. White DL, Dang P, Engler J et al. Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib. J Clin Oncol 2010;28:2761-2767.
48. Donato NJ, Wu JY, Stapley J et al. BCR-ABL independence and LYN ki-nase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 2003;101:690-698.
49. Wu J, Meng F, Kong LY et al. Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase. J Natl Cancer Inst 2008;100:926-939.
50. Hayette S, Chabane K, Michallet M et al. Longitudinal studies of SRC family kinases in imatinib- and dasatinib-resistant chronic myeloid leukemia patients. Leuk Res 2011;35:38-43.
51. Schnittger S, Bacher U, Dicker F et al. Associations between imatinib resistance conferring mutations and Philadelphia positive clonal cytogenetic evolution in CML. Genes Chromosomes Cancer 2010;49:910-918.
52. Noens L, van Lierde MA, De Bock R et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic my-eloid leukemia: The ADAGIO study. Blood 2009;113:5401-5411.
53. Marin D, Bazeos A, Mahon FX et al. Adherence is a critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 2010;28:2381-2388.
54. Tanaka C, Yin OQ, Sethuraman V et al. Clinical pharmacokinetics of the BCR-ABL tyrosine kinase inhibitor nilotinib. Clin Pharmacol Ther 2010; 87:197-203.
55. Tanaka C, Yin OQ, Smith T et al. Effects of rifampin and ketoconazole on the pharmacokinetics of nilotinib in healthy participants. J Clin Pharmacol 2011;51:75-83.
56. Dulucq S, Bouchet S, Turcq B et al. Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 2008;112:2024-2027.
57. Kim DH, Sriharsha L, Xu W et al. Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia. Clin Cancer Res 2009;15: 4650-4758.
58. Ni LN, Li JY, Miao KR et al. Multidrug resistance gene (MDR1) polymorphisms correlate with imatinib response in chronic myeloid leukemia. Med Oncol 2011;28:265-269.
59. Bazeos A, Marin D, Reid AG et al. hOCT1 transcript levels and single nu-cleotide polymorphisms as predictive factors for response to imatinib in chronic myeloid leukemia. Leukemia 2010;24:1243-1245.
60. Laneuville P, Dilea C, Yin OQ, et al. Comparative in vitro cellular data alone are insufficient to predict clinical responses and guide the choice of BCR-ABL inhibitor for treating imatinib-resistant chronic myeloid leukemia. J Clin Oncol 2010;28:e169-e171; author reply e172.
61. Gruber FX, Lamark T, Anonli A et al. Selecting and deselecting imatinib-resistant clones: Observations made by longitudinal, quantitative monitoring of mutated BCR-ABL. Leukemia 2005;19:2159-2165.
62. Pelz-Ackermann O, Cross M, Pfeifer H et al. Highly sensitive and quantitative detection of BCR-ABL kinase domain mutations by ligation PCR. Leukemia 2008;22:2288-2291.
63. Ernst T, Gruber FX, Pelz-Ackermann O et al. A co-operative evaluation of different methods of detecting BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on second-line dasatinib or nilotinib therapy after failure of imatinib. Haematologica 2009;94:1227-1235.
64. Willis SG, Lange T, Demehri S et al. High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: Correlation with clonal cytogenetic evolution but not response to therapy. Blood 2005;106: 2128-2137.
65. Sherbenou DW, Wong MJ, Humayun A et al. Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable complete cytoge-netic response to imatinib. Leukemia 2007;21:489-493.